Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis (original) (raw)
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Vincenzo Parrino
Advances in Rheumatology
View PDFchevron_right
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Rossana Scrivo
Expert Opinion on Biological Therapy
View PDFchevron_right
Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath
Charlotte Cavill
Clinical Rheumatology, 2020
View PDFchevron_right
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
Alan Kivitz
RMD Open, 2019
View PDFchevron_right
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Ricardo Blanco
Arthritis research & therapy, 2017
View PDFchevron_right
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA
Yusuf Patel
Rheumatology Advances in Practice
View PDFchevron_right
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
Rubén Queiro
Frontiers in Medicine
View PDFchevron_right
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Helena Marzo-ortega
Annals of the rheumatic diseases, 2016
View PDFchevron_right
Effectiveness and safety of secukinumab in ankylosing spondylitis: real life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
Adeola Ajibade
Rheumatology Advances in Practice, 2023
View PDFchevron_right
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
Mariagrazia Lorenzin
RMD Open
View PDFchevron_right
Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
blessing dube
The Journal of Rheumatology
View PDFchevron_right
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
Helena Marzo-ortega
Rheumatology and Therapy, 2021
View PDFchevron_right
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
Alan Kivitz
Arthritis care & research, 2017
View PDFchevron_right
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
Ricardo Blanco
RMD open, 2017
View PDFchevron_right
Secukinumab treatment in spondyloarthritis: Retention rate and effectiveness data at 12 months – data from the Romanian Registry of Rheumatic Diseases
Simona Rednic
Romanian Journal of Rheumatology, 2020
View PDFchevron_right
SAT0430 SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK
Björn Guðbjörnsson
Annals of the Rheumatic Diseases, 2020
View PDFchevron_right
Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: A Phase 3 randomized trial (MEASURE 1)
vibeke strand
Arthritis & rheumatology (Hoboken, N.J.), 2016
View PDFchevron_right
Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
Carlos A Guillen Astete
Rheumatology and therapy, 2021
View PDFchevron_right
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study
Juergen Rech
ACR Open Rheumatology
View PDFchevron_right
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Stephan Bek
The Lancet, 2013
View PDFchevron_right
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
Roberta Ramonda
Research Square (Research Square), 2024
View PDFchevron_right
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
Todd Fox
The Journal of Rheumatology, 2021
View PDFchevron_right
AB0761 SECUKINUMAB for the Treatment of Psoriatic Arthritis in Real Life: An Italian Experience
Roberta Ramonda
Abstracts accepted for Publication, 2019
View PDFchevron_right
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers
Giovanni Lapadula
The Israel Medical Association journal : IMAJ, 2018
View PDFchevron_right
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients
Ana-maria Orbai
The Journal of Rheumatology, 2019
View PDFchevron_right
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Alan Kivitz
The Journal of rheumatology, 2016
View PDFchevron_right
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
Todd Fox
Arthritis Research & Therapy, 2018
View PDFchevron_right
Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
Helena Marzo-ortega
ACR Open Rheumatology, 2020
View PDFchevron_right
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
Helena Marzo-ortega
Arthritis Research & Therapy, 2021
View PDFchevron_right
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
DAMIEN LOEUILLE
Rheumatology, 2020
View PDFchevron_right